STOCK TITAN

Tiziana Life Sciences Ltd - TLSA STOCK NEWS

Welcome to our dedicated news page for Tiziana Life Sciences (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tiziana Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tiziana Life Sciences's position in the market.

Rhea-AI Summary
Tiziana Life Sciences Ltd. presents positive data on intranasal anti-CD3 monoclonal antibody for Alzheimer’s and Parkinson’s disease at AD/PD conference. The data shows reduction in microglia activation and improvement in behavior in rodent models. Nasal anti-CD3 also reduces hemorrhage and edema associated with ARIA. Neuroinflammation modulation may enhance approved treatments for Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.6%
Tags
none
-
Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced positive findings in a study of patients with na-SPMS, showing improvements in fatigue scores and reduction in microglial activation. The Company is developing breakthrough neuro-immunomodulation therapies and has seen promising results in the Expanded Access (EA) patients. The study is being led by prominent figures in the medical field and has potential implications for the ongoing Phase 2 clinical trial of intranasal foralumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none
-
Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, on January 8-10, 2024. The presentation will focus on the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced the filing of a new patent application for combining GLP-1ra and foralumab to reduce systemic and vascular inflammation associated with Type 2 Diabetes and non T2D obesity. The application describes the potential for foralumab to provide additional risk reduction for major adverse cardiovascular events. The company aims to provide a new therapeutic option for patients receiving GLP-1 receptor antagonists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the dosing of the first patient in its Phase 2a study for intranasal foralumab in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The trial aims to compare two doses of foralumab and placebo, with a primary endpoint of change in microglial activation based on PET scans. The study also includes assessments of clinical parameters and immuno-biomarkers. The company hopes to provide a new therapeutic option for na-SPMS patients, as there are currently no FDA-approved treatments for this condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
clinical trial
-
Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on December 6th at 3:00 PM ET. The presentation will focus on recent clinical updates and Phase 2 trial of intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) has enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access (EA) Program. A total of ten patients are now being followed in the EA Program, marking a critical step forward in Tiziana Life Sciences' mission to provide treatment options for patients living with this debilitating disease while collecting valuable regulatory evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
Rhea-AI Summary
Tiziana Life Sciences (TLSA) announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, will present at BIO-Europe in Munich, Germany. The presentation will focus on the clinical updates of intranasal foralumab for the treatment of diseases like multiple sclerosis and Alzheimer's. The company's management will also participate in one-on-one partnering meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Tiziana Life Sciences receives FDA approval for multiple sclerosis patients to self-administer Intranasal Foralumab at home
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
Rhea-AI Summary
Tiziana Life Sciences announces positive results in Expanded Access Program for foralumab in na-SPMS patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
Tiziana Life Sciences Ltd

Nasdaq:TLSA

TLSA Rankings

TLSA Stock Data

41.83M
61.41M
43.47%
0.78%
0.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
London

About TLSA

tiziana life sciences plc is a uk biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. the company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (cdk) involved in cell division as well as a number of other protein kinases. milciclib is currently in phase ii clinical trials for thymic carcinoma in patients previously treated with chemotherapy. the company is also in clinical development of foralumab. foralumab is the only fully human engineered anti-human cd3 antibody in clinical development. this phase ii compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (t1d), inflammatory bowel disease (ibd), psoriasis and rheumatoid arthritis, where modulation of a t-cell response is desirable. tiziana life sciences’ research